Entry37.38→Now37.65
Long IMVT ahead of positive Phase 2 CLE readout Open original source
IMVT Immunovant, Inc. Loading... : Investor Sentiment and Bull/Bear Views
Loading chart...
Top Calls
Price change since each call, adjusted for long/short direction. Results calculated:
Feed
14:00
Sep 14
Sep 14
Long IMVT ahead of positive Phase 2 CLE readout
Immunovant's Phase 2 trial for IMVT-1402 in Cutaneous Lupus is expected to read out positively, with the author assigning a 65-70% probability of success based on FcRn inhibition reducing pathogenic IgG autoantibodies and validation from J&J's Nipocalimab in SLE. The catalyst is the Phase 2 topline readout (estimated primary completion October 2026), with a target price of $45-$50 from the current ~$37, implying ~35% upside. The main risk is that early proof-of-concept data was from a small, open-label study without placebo control, and SLE is different from CLE.
HIGH
13:05
Aug 17
Aug 17
Shares options positioning net conviction data.
Shares options positioning data showing net conviction based on fund holdings, no directional view.
MED
12:56
Aug 17
Aug 17
Reports heaviest selling across specialist funds
"Reports net conviction laggards with heaviest genuine selling across specialist funds in Q2 2026, no directional view."
MED
01:11
Jan 09
Jan 09
IMVT 100% upside, insider buy, phase 3 catalyst
The author notes Immunovant received a $50 price target from Wolfe Research, implying 100% upside from the current ~$25 level. Additional buy analyst ratings and a $350 million insider buy are cited as bullish signals ahead of phase 3 results. The 20% short float is mentioned as potential fuel for a squeeze.
MED
About IMVT Investor Commentary
Across the available history and selected sources, Buzzberg tracks IMVT (Immunovant, Inc.) across 2 sources: 2 bullish vs 0 bearish calls from 3 authors. Historical directional balance: 50% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 4 total trade ideas tracked. Past 7 days, before deduplication: 1 bullish. Latest voices: u/Nix_100, seedy19tron, u/BOOMHOTSTOCKS.